ESK-001

Phase 2Small molecule

AAlumis Inc

ESK-001 is one of 40 small molecule programs targeting Plaque Psoriasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plaque PsoriasisActive, not recruiting

FunctionRecruiting

Plaque PsoriasisPhase 2

Active, not recruiting

FunctionPhase 1

Recruiting

Competition

Competitive Landscape

45 competitors in Function

#DrugCompanyPhaseTrials

Indocin

CCosette Pharmaceuticals, Inc.

Approved

3 2

Flomax

Sanofi

Phase 3

1 3

N-Acetyl Cyteien

SStanford University

Phase 3

2 4

Ezallor Sprinkle

AstraZeneca

Phase 2

1 5

Golytely

Bayer

Phase 1

1 6

Activella

Eli Lilly

Preclinical

1 7

Spinraza

Biogen

Preclinical

1 8

RAY1225

GGuangdong Raynovent Biotech Co., Ltd

Phase 1

2 9

GZR18

GGan & Lee Pharmaceuticals.

Phase 1

1 10

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

SLE

NCT05966480

Q4 2027

Phase 2Active, not recruiting

Plaque Psoriasis

NCT05739435

Clinical

Trials by Indication[1]

Plaque Psoriasis3 trials

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (ONWARD1)

Completed·AAlumis Inc·Phase 3·NCT06586112·912 enrolled

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)

Completed·AAlumis Inc·Phase 3·NCT06588738·862 enrolled

A Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Patients With Plaque Psoriasis

Active, not recruiting·AAlumis Inc·Phase 2·NCT05739435·165 enrolled

ART1 trial

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

Completed·AAlumis Inc·Phase 1·NCT05330858·14 enrolled

Function1 trial

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

Recruiting·AAlumis Inc·Phase 1·NCT06952634·48 enrolled

Cardiac1 trial

An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001

Completed·AAlumis Inc·Phase 1·NCT07378579·52 enrolled

Efficacy and Safety1 trial

POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU

Terminated·AAlumis Inc·Phase 2·NCT05953688·36 enrolled

3 more indications

Psoriasis1 trial

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Completed·AAlumis Inc·Phase 2·NCT05600036·228 enrolled

Impaired Renal Function1 trial

An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

Completed·AAlumis Inc·Phase 1·NCT06962774·16 enrolled

SLE1 trial

A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients With Systemic Lupus Erythematosus

Active, not recruiting·AAlumis Inc·Phase 2·NCT05966480·408 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for ESK-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ESK-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ESK-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alumis Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAlumis Inc

ESK-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Trials by Indication[1]

Plaque Psoriasis3 trials

ART1 trial

Function1 trial

Cardiac1 trial

Efficacy and Safety1 trial

Psoriasis1 trial

Impaired Renal Function1 trial

SLE1 trial

References

Drug Info

Quick Facts

Related News